Target market Small biotech labs and contract research organizations in need of high-sensitivity multispectral imaging and quantitative tissue analysis to accelerate drug discovery; leverage CRi’s niche positioning and recent acquisition history to align with buyers seeking enhanced in vivo and tissue imaging capabilities.

Product fit Highlight opportunities with researchers requiring multiplexed imaging and quantitative biomarker readouts in intact tissue, cellular samples, or small animal models; emphasize unique algorithms and rapid, cost-effective imaging to differentiate from broader imaging vendors.

Partner potential Explore channel partnerships with larger imaging and diagnostics players that integrate specialty imaging capabilities into their portfolios, leveraging CRi’s technology as an embedded or add-on solution to expand market reach.

Strategic expansion Given the historical acquisition activity in the imaging space, identify prospects in organizations consolidating BIotech instrumentation portfolios or expanding in vivo imaging offerings, with a focus on channels that value integrated hardware and analytics.

Competitive positioning Position CRi as a cost-efficient, high-sensitivity multispectral option for academic and early-stage industry customers facing budget constraints, while underscoring fast deployment, scalable analysis, and potential for co-development on disease or drug response markers.